Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis

Julie Anne G Mcgregor,Susan L. Hogan,Elizabeth S. Kotzen,Caroline J. Poulton,Yichun Hu,Roberto Negrete-López,Jason Kidd,Suzanne L. Katsanos,Donna O. Bunch,Patrick H. Nachman,Ronald J. Falk

Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis

2015

Julie Anne G Mcgregor
Susan L. Hogan
Elizabeth S. Kotzen
Caroline J. Poulton
Yichun Hu
Roberto Negrete-López
Jason Kidd
Suzanne L. Katsanos
Donna O. Bunch
Patrick H. Nachman
Ronald J. Falk

Background Rituximab has been used in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) since 2003. Our objective was to describe outcomes and adverse events following rituximab since that time in an inception cohort.

Keywords:

Rituximab
Anti-neutrophil cytoplasmic antibody
Vasculitis
Glomerulonephritis
Immunology
Adverse effect
Survival rate
Cyclophosphamide
Medicine
Immunosuppression

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations